Summary
Becton Dickinson and Company (BDX) reported its fiscal first quarter 2015 results for the period ending December 31, 2014. The company announced a 1.8% increase in revenue to $2.051 billion, driven by volume growth partially offset by unfavorable foreign currency translation. Net income decreased to $236 million from $271 million in the prior year period, leading to diluted earnings per share of $1.20, down from $1.37. This decrease was influenced by significant acquisition-related costs, litigation charges, and financing expenses associated with the pending acquisition of CareFusion Corporation, which was announced during the quarter. The balance sheet shows a significant increase in cash and equivalents to $8.54 billion from $1.86 billion, largely due to proceeds from debt issuance to finance the CareFusion acquisition. Long-term debt also saw a substantial rise to $9.94 billion from $3.77 billion. Investors should note the strategic shift with the pending acquisition of CareFusion, which is expected to close by the second quarter of fiscal year 2015, creating a larger entity focused on medication management and patient safety. While the company's financial position remains strong, the increased debt and integration efforts related to the acquisition will be key areas to monitor.
Financial Highlights
50 data points| Revenue | $2.05B |
| Cost of Revenue | $1.01B |
| Gross Profit | $1.04B |
| R&D Expenses | $129.00M |
| SG&A Expenses | $544.00M |
| Operating Expenses | $1.70B |
| Operating Income | $349.00M |
| Interest Expense | $76.00M |
| Net Income | $236.00M |
| EPS (Basic) | $1.22 |
| EPS (Diluted) | $1.20 |
| Shares Outstanding (Basic) | 192.84M |
| Shares Outstanding (Diluted) | 197.00M |
Key Highlights
- 1Revenue increased by 1.8% to $2.05 billion, driven by volume growth, offset by a 3.5% unfavorable foreign currency translation.
- 2Net income decreased to $236 million ($1.20 EPS) from $271 million ($1.37 EPS) in the prior year, impacted by acquisition-related costs and litigation charges.
- 3Significant increase in cash and equivalents to $8.54 billion from $1.86 billion, primarily due to $6.2 billion in senior unsecured notes issued to finance the pending CareFusion acquisition.
- 4Long-term debt increased substantially to $9.94 billion from $3.77 billion, reflecting the financing for the CareFusion acquisition.
- 5The company announced a definitive agreement to acquire CareFusion Corporation for approximately $12.2 billion, a major strategic move expected to close by Q2 FY2015.
- 6Operating income for the Medical segment increased slightly to $304 million, while Life Sciences operating income decreased to $214 million.
- 7Share repurchase program was suspended for FY2015 due to the pending CareFusion acquisition.